The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Tafasitamab, lenalidomide, and R-CHOP in frontline high-risk DLBCL: the Phase III frontMIND trial
Georg Lenz, MD, University of Münster, Münster, Germany, discusses the results of the Phase III frontMIND trial (NCT04824092), which compared the safety and efficacy of tafasitamab plus lenalidomide and R-CHOP versus R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL). Prof. Lenz highlights that the tafasitamab-containing combination therapy showed improved progression-free and overall survival, as well as higher rates of measurable residual disease (MRD) negativity, and notes that the next steps will involve identifying the specific patient subtypes that will benefit most from this therapeutic approach. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This was an internationally conducted phase 3 trial that compared the standard of care R-CHOP to Tafasitamab-lenalidomide-R-CHOP in previously untreated patients with high-risk aggressive lymphomas. I think the key finding is really that Tafasitamab-Len-R-CHOP is more efficacious compared to R-CHOP alone, especially with respect to progression-free and overall survival...
This was an internationally conducted phase 3 trial that compared the standard of care R-CHOP to Tafasitamab-lenalidomide-R-CHOP in previously untreated patients with high-risk aggressive lymphomas. I think the key finding is really that Tafasitamab-Len-R-CHOP is more efficacious compared to R-CHOP alone, especially with respect to progression-free and overall survival. And also the MRD negativity was higher in the Tafasitamab-Len-R-CHOP arm, implying and suggesting that the remissions that we obtain by this regimen are deeper. There was more toxicity induced by Tafasitamab-Len-R-CHOP, but I think overall this was manageable. I mean, this was a high risk population between 18 and 80 years old. So people really in demand of good therapies because their risk is rather high not to respond to the first line therapy. I mean, assuming that it’s gets approved and reimbursed, I think this will be adapted in the clinic. So next steps, which are of major importance, are really to identify the specific patient, the specific subtype of patient that will benefit from this therapy. Another standard is Pola-R-CHP. And that’s also a good therapy. So we have to find the exact patient for which therapy. And I think that will be the major task in the next couple of years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
